Optimizing sample size in relative bioavailability trials using a Bayesian decision-theoretic framework

DOI10.1080/07474946.2020.1766887zbMath1473.62370OpenAlexW3086243165MaRDI QIDQ4964398

Paul Meyvisch

Publication date: 2 March 2021

Published in: Sequential Analysis (Search for Journal in Brave)

Full work available at URL: https://doi.org/10.1080/07474946.2020.1766887

zbMATH Keywords

decision theorybioequivalencebioavailabilitypharmacokinetic (PK) parameter

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10) Point estimation (62F10) Bayesian problems; characterization of Bayes procedures (62C10) Kinetics in biochemical problems (pharmacokinetics, enzyme kinetics, etc.) (92C45) Sequential statistical design (62L05)

Cites Work

• PILOT TRIAL FOR THE ASSESSMENT OF RELATIVE BIOAVAILABILITY IN GENERIC DRUG PRODUCT DEVELOPMENT: STATISTICAL POWER
• Sample Size Determination for Phase II Clinical Trials Based on Bayesian Decision Theory

This page was built for publication: Optimizing sample size in relative bioavailability trials using a Bayesian decision-theoretic framework